Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank

View ORCID ProfileXikang Fan, Cheng Yin, View ORCID ProfileJiayu Wang, View ORCID ProfileMingjia Yang, Hongxia Ma, Guangfu Jin, Mingyang Song, Zhibin Hu, Hongbing Shen, View ORCID ProfileDong Hang
doi: https://doi.org/10.1101/2020.07.09.20149369
Xikang Fan
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Xikang Fan
Cheng Yin
2Department of Laboratory, Jiangning Hospital Affiliated to Nanjing Medical University, Nanjing, China, 211100
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jiayu Wang
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jiayu Wang
Mingjia Yang
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mingjia Yang
Hongxia Ma
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
3State Key Laboratory of Reproductive Medicine, Center for Global Health, Nanjing Medical University, Nanjing, China, 211166
4Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Guangfu Jin
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
3State Key Laboratory of Reproductive Medicine, Center for Global Health, Nanjing Medical University, Nanjing, China, 211166
4Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mingyang Song
5Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 02115
6Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA, 02115
7Clinical and Translational Epidemiology Unit and Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, 02114
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhibin Hu
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
3State Key Laboratory of Reproductive Medicine, Center for Global Health, Nanjing Medical University, Nanjing, China, 211166
4Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hongbing Shen
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
4Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Dong Hang
1Department of Epidemiology and Biostatistics, International Joint Research Center on Environment and Human Health, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, China, 211166
4Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, Nanjing Medical University, Nanjing, China, 211166
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Dong Hang
  • For correspondence: hangdong{at}njmu.edu.cn
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Coronavirus disease 2019 (COVID-19) deteriorates suddenly primarily due to excessive inflammatory injury, and insulin-like growth factor-1 (IGF-1) is implicated in endocrine control of the immune system. However, the effect of IGF-1 levels on COVID-19 prognosis remains unknown.

Objective To investigate the association between circulating IGF-1 concentrations and mortality risk among COVID-19 patients.

Design Prospective analysis.

Setting UK Biobank.

Participants 1425 COVID-19 patients who had pre-diagnostic serum IGF-1 measurements at baseline (2006-2010).

Main outcome measures COVID-19 mortality (available death data updated to 22 May 2020). Unconditional logistic regression was performed to estimate the odds ratio (OR) and 95% confidence intervals (CIs) of mortality across the IGF-1 quartiles.

Results Among 1425 COVID-19 patients, 365 deaths occurred due to COVID-19. Compared to the lowest quartile of IGF-1 concentrations, the highest quartile was associated with a 37% lower risk of mortality (OR: 0.63, 95% CI: 0.43-0.93, P-trend=0.03). The association was stronger in women and nonsmokers (both P-interaction=0.01).

Conclusions Higher IGF-1 concentrations are associated with a lower risk of COVID-19 mortality. Further studies are required to determine whether and how targeting IGF-1 pathway might improve COVID-19 prognosis.

Introduction

An outbreak of Coronavirus Disease 2019 (COVID-19) began in December 2019 and has triggered a public health emergency of international concern 1. The majority of COVID-19 patients have a self-limiting infection and recover, but some suffer severe symptoms and even die 2. The suddenly deteriorating conditions of some patients are mainly attributed to systematic inflammatory injury caused by the excessive or uncontrolled activation of immune response, known as the cytokine storm, leading to respiratory distress syndrome (ARDS) and multiple organ failure 3.

Insulin-like growth factor 1 (IGF-1) belongs to the IGF family that plays a critical role in diverse biological activities including cell proliferation, metabolism, differentiation, and survival 4. Cumulative evidence also supports that IGF-1 pathway can regulate the immune response via interaction with various cytokines (e.g., interferons) and immune cells such as T lymphocytes, macrophages, and bone marrow cells 5. IGF-1 may act as an important switch controlling the amplitude and quality of the immune response 6. Of note, IGF-1 administration is already an approved therapy for growth failure and may improve symptoms of autoimmune diseases such as type-1 diabetes and multiple sclerosis 7. However, whether IGF-1 plays a role in COVID-19 prognosis remains unknown.

Therefore, in the current study, we used the UK Biobank resource, with recently released data on COVID-19 tests and updated death records, to investigate the association between pre-diagnostic serum IGF-1 concentrations and mortality among COVID-19 patients.

Methods

Study Participants

UK Biobank is a prospective cohort study consisting of approximately half a million participants (aged 37-73 years) recruited across the UK between 2006 and 2010 8. Up to 22 May 2020, among 5516 participants who had undergone COVID-19 PCR tests provided by Public Health England, 1422 patients were diagnosed with COVID-19. In the current analysis, we also included additional 150 patients who died from COVID-19 according to the National Health Service death records. The patients who had no available data on serumIGF-1 (n=140) or died from other causes (n=7, including colon cancer, lung cancer, dementia, chronic ischaemic heart disease, and bronchopneumonia) were excluded, leaving 1425 patients in the final analysis.

Assessment of IGF-1

Details about serum biomarker measurements and assay performances have been described online (http://biobank.ndph.ox.ac.uk/showcase/showcase/docs/serum_biochemistry.pdf). Briefly, serum concentrations of IGF-1 were measured in UK Biobank’s purpose-built facility using a ‘one step sandwich’ Chemiluminescent Immunoassay method based on DiaSorin Liaison XL Analyzer (Diasorin S.p.A), with a detection range of 1.3-195 nmol/L. The average coefficients of variation of IGF-1 derived from internal quality control samples of known high, medium, and low concentrations were 6.18%, 5.29%, and 6.03%, respectively.

Moreover, the assay of serum IGF-1 was registered with an external quality assurance (EQA) scheme (RIQAS Immunoassay Speciality 1) to verify accuracy. The EQA results showed that 100% of participated distributions (n=105) were good or acceptable.

Ascertainment of COVID-19 Mortality

Dates and causes of death were obtained from death certificates held by the National Health Service Information Centre (England and Wales) and the National Health Service Central Register Scotland (Scotland) 9. The outcome of current study was mortality due to COVID-19 (ICD-10 U07) and available death data were updated to 22 May 2020.

Ascertainment of Covariates

At baseline, participants attended one of 22 assessment centers across England, Scotland, and Wales where they completed a touch-screen, self-completed questionnaire. Ethnicity, smoking status, and alcohol intake were self-reported. Height and body weight were measured by trained nurses at baseline, and body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Townsend deprivation index was derived from residence using data on car and home ownership, unemployment, and household overcrowding. Physical activity was measured as total metabolic equivalent task-minutes per week for all activity including walking, moderate and vigorous activity.

Statistical Analysis

Because the date of COVID-19 testing did not represent the time of infection, the survival time for each patient could not be accurately estimated, leading to Cox regression models inapplicable in the current analysis. Therefore, we analyzed the association between IGF-1 and COVID-19 mortality using unconditional logistic regression models. Odds ratios (OR) and 95% confidence intervals (CI) for each quartile of IGF-1 were calculated, with the lowest quartile as the reference. Model 1 was adjusted for major covariates including age at infection, sex, and ethnicity; Model 2 was further adjusted for Townsend deprivation index, BMI, smoking status, alcohol drinking, and physical activity. We also additionally adjusted for C-reactive protein in those who had the inflammatory biomarker data (n=1418), and the results were essentially unchanged (data not shown).

Stratified analyses were conducted according to the median age at infection (<70, ≥70 years), sex (male, female), BMI (<30, ≥30 kg/m2), physical activity (≤median, >median), and smoking status (never, ever) in the fully-adjusted model. To investigate potential effect modification by these stratification variables, we used a likelihood ratio test comparing the models with and without interaction terms between IGF-1 concentrations and each of the stratification variables.

Sensitivity analyses were performed by excluding participants with baseline cancer or cardiovascular disease. We used SAS 9.4 for all analyses. All statistical tests were two-sided, and P <0.05 was defined as statistically significant.

Results

Among 1425 COVID-19 patients, 365 deaths occurred due to COVID-19. The median time from baseline blood draw to COVID-19 testing was 11.1 years (interquartile range: 10.5-11.8 years). The distribution of IGF-1 concentrations is shown in Figure 1, ranging from 4.79 to 46.09 nmol/L, which was similar to the distribution in the whole cohort (data not shown).

Figure 1.
  • Download figure
  • Open in new tab
Figure 1. The distribution histogram of IGF-1 concentrations.

Table 1 summarizes the main characteristics of COVID-19 patients according to quartiles of serum IGF-1 concentrations. At baseline, participants with higher IGF-1 had a lower BMI and higher levels of physical activity, and tended to be younger, males, and nonsmokers.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 1. Baseline characteristics of COVID-19 patients according to quartiles of serum IGF-1 concentrations

As shown in Table 2, higher IGF1 concentrations were associated with a reduced risk of COVID-19 mortality in the multivariable models (Model 1, OR comparing quartile 5 verse 1: 0.58, 95% CI: 0.39-0.85, P-trend=0.01). The association remained stable after further adjustment for the other confounders (Model 2, OR: 0.63, 95% CI: 0.43-0.93, P-trend=0.03).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 2. Association between serum IGF-1 concentrations and COVID-19 mortality

Figure 2 shows the forest plot results of stratified analyses. The inverse associations of IGF-1 with a COVID-19 mortality were largely consistent across subgroups, except for sex and smoking status. The association appeared to be stronger in women and nonsmokers (both P-interaction=0.01).

Figure 2.
  • Download figure
  • Open in new tab
Figure 2. Forest plots of stratified analysis for the associations between serum IGF-1 concentrations and the risk of COVID-19 mortality.

Sensitivity analyses showed that the aforementioned associations remained basically unchanged after excluding 238 individuals who had baseline cancer or cardiovascular disease (Table 3).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table 3. Association between serum IGF-1 concentrations and COVID-19 mortality after excluding participants with baseline cancer or vascular disease (n=238)

Discussion

To the best of our knowledge, this study was the first to demonstrate an inverse association between pre-diagnostic circulating levels of IGF-1 and COVID-19 mortality risk among COVID-19 patients, particularly for women and nonsmokers. Our findings suggest that IGF-1 might play a role in COVID-19 prognosis.

Cytokine storm has been recognized as one of the major causes of ARDS and multiple organ failure in COVID-19 patients. Therefore, effectively suppressing the cytokine storm is important to prevent the disease deterioration and reduce COVID-19 mortality. Markedly elevated levels of circulating IL-6, IL-2R, IL-10, TNFα, etc. have been detected in patients with severe COVID-19 10,11. These cytokines are mainly produced by macrophages and lymphocytes which have been implicated in cytokine storm 12. Several studies in humans and animal models have suggested an anti-inflammatory effect of IGF-1. For example, there is an inverse relationship between circulating IGF-1 and IL-6 levels 13,14, and IGF-1/IGF binding protein-3 administration to severely burned patients effectively attenuated inflammatory effects and reduced IL-6 levels 15. Recombinant human IGF-1 infusion into ApoE-deficient mice significantly decreased macrophage infiltration by downregulating IL-6 and TNF-α expression 16. In addition, recombinant human IGF-1 can mediate autoimmune suppression in mouse models of autoimmune disease by increasing regulatory T cells in affected tissues 7. However, it remains uncertain whether gender and smoking status modify the role of IGF-1 in immune regulation, and other studies also reported that IGF-1 might exert pro-inflammatory effects 17,18. Future studies are necessary to clarify the mechanism of IGF-1 in COVID-19 prognosis.

Our study has several strengths. First, UK Biobank is a well-designed large cohort and are providing reliable data on COVID-19 diagnosis and related deaths, allowing us to do the analysis in a timely fashion. Second, biochemistry assays of IGF-1 were performed in a single dedicated central laboratory by a standard, reliable method and strict quality control procedures. Third, we were able to adjust for various covariates on demographic and lifestyle factors.

Several potential limitations also need to be acknowledged. First, the observational nature of this study prevents us from inferring causality. However, our sensitivity analyses excluding baseline CVD and cancer supported the robustness of the findings. Second, given the lack of repeated IGF-1 measurements, we were unable to analyze the relationship between dynamic IGF-1 concentrations and COVID-19 mortality. However, we calculated the intraclass correlation coefficient (ICC) between IGF1 measurements collected 4 years apart in a subcohort (n= 16,356). The ICC value of 0.78, consistent with the previous data 19, indicates that IGF1 levels are generally stable over time. Third, due to limited coverage of coronavirus testing in the UK, ascertainment bias cannot be avoided. In addition, UK Biobank is not a representative sample of the UK population 20, limiting ability to generalize the results to the whole UK or other populations.

Conclusions

The current study indicates that higher serum IGF-1 concentrations are associated with a lower risk of COVID-19 mortality. Further studies are warranted to validate our findings and clarify underlying mechanisms.

Data Availability

The data that support the findings of this study are available from UK Biobank (https://www.ukbiobank.ac.uk/), but restrictions apply to their availability. These data were used under licence for the current study and so are not publicly available. The data are available from the authors upon reasonable request and with permission of UK Biobank.

http://biobank.ndph.ox.ac.uk/showcase/

Author Contributions

DH was responsible for the conception and design of the study. XF and DH had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the data analysis. XF and CY did the statistical analysis and drafted the manuscript. JW, MY, HM, GJ, MS, ZH, and HS critically revised the manuscript for important intellectual content. All authors reviewed and approved the final manuscript.

Disclosure Summary

The authors have nothing to disclose.

Acknowledgments

We are grateful to UK Biobank participants. This research has been conducted using the UK Biobank resource under application number 52217.

Footnotes

  • ↵* Co-first authors, contributed equally.

  • Funding This study was funded by National Natural Science Foundation of China (81820108028, 81521004, and 81973127), National Key R&D Program of China (2016YFC1000200 and 2017YFC0908300), and Science Foundation for Excellent Young Scholars of Jiangsu (BK20190083). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Abbreviations

COVID-19
coronavirus disease 2019
BMI
body mass index
MET
metabolic equivalent
ICD
international classification of diseases
OR
odds ratio
CI
confidence interval.

References

  1. 1.↵
    Lai CC, Shih TP, Ko WC, et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020;55(3):105924. doi: 10.1016/j.ijantimicag.2020.105924
    OpenUrlCrossRefPubMed
  2. 2.↵
    Azkur AK, Akdis M, Azkur D, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020 doi: 10.1111/all.14364
    OpenUrlCrossRefPubMed
  3. 3.↵
    Ye Q, Wang B, Mao J. The pathogenesis and treatment of the ‘Cytokine Storm’ in COVID-19. J Infect 2020;80(6):607–13. doi: 10.1016/j.jinf.2020.03.037
    OpenUrlCrossRefPubMed
  4. 4.↵
    Stewart CE, Rotwein P. Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 1996;76(4):1005–26. doi: 10.1152/physrev.1996.76.4.1005
    OpenUrlCrossRefPubMedWeb of Science
  5. 5.↵
    Skarlis C, Nezos A, Mavragani CP, et al. The role of insulin growth factors in autoimmune diseases. Annals of Research Hospitals 2019;3
  6. 6.↵
    Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010;62(2):199–236. doi: 10.1124/pr.109.002469
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    Bilbao D, Luciani L, Johannesson B, et al. Insulin-like growth factor-1 stimulates regulatory T cells and suppresses autoimmune disease. EMBO Mol Med 2014;6(11):1423–35. doi: 10.15252/emmm.201303376
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    Collins R. What makes UK Biobank special? Lancet 2012;379(9822):1173–4. doi: 10.1016/S0140-6736(12)60404-8
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    Sudlow C, Gallacher J, Allen N, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med 2015;12(3):e1001779. doi:10.1371/journal.pmed.1001779
    OpenUrlCrossRefPubMed
  10. 10.↵
    Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130(5):2620–29. doi: 10.1172/JCI137244
    OpenUrlCrossRefPubMed
  11. 11.↵
    Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506. doi: 10.1016/S0140-6736(20)30183-5
    OpenUrlCrossRefPubMed
  12. 12.↵
    Arango Duque G, Descoteaux A. Macrophage cytokines: involvement in immunity and infectious diseases. Front Immunol 2014;5:491. doi: 10.3389/fimmu.2014.00491
    OpenUrlCrossRefPubMed
  13. 13.↵
    Rajpathak SN, McGinn AP, Strickler HD, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res 2008;18(2):166–73. doi: 10.1016/j.ghir.2007.08.004
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    Succurro E, Andreozzi F, Sciacqua A, et al. Reciprocal association of plasma IGF-1 and interleukin-6 levels with cardiometabolic risk factors in nondiabetic subjects. Diabetes Care 2008;31(9):1886–8. doi: 10.2337/dc08-0553
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    Spies M, Wolf SE, Barrow RE, et al. Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med 2002;30(1):83–8. doi: 10.1097/00003246-200201000-00013
    OpenUrlCrossRefPubMedWeb of Science
  16. 16.↵
    Sukhanov S, Higashi Y, Shai SY, et al. IGF-1 reduces inflammatory responses, suppresses oxidative stress, and decreases atherosclerosis progression in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2007;27(12):2684–90. doi: 10.1161/ATVBAHA.107.156257
    OpenUrlAbstract/FREE Full Text
  17. 17.↵
    Li G, Zhou L, Zhang C, et al. Insulin-Like Growth Factor 1 Regulates Acute Inflammatory Lung Injury Mediated by Influenza Virus Infection. Front Microbiol 2019;10:2541. doi: 10.3389/fmicb.2019.02541
    OpenUrlCrossRef
  18. 18.↵
    Wolters TLC, Netea MG, Hermus A, et al. IGF1 potentiates thepro-inflammatory response in human peripheral blood mononuclear cells via MAPK. J Mol Endocrinol 2017;59(2):129–39. doi: 10.1530/JME-17-0062
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    Goodman-Gruen D, Barrett-Connor E. Epidemiology of insulin-like growth factor-I in elderly men and women. The Rancho Bernardo Study. Am J Epidemiol 1997;145(11):970–6. doi: 10.1093/oxfordjournals.aje.a009065
    OpenUrlCrossRefPubMedWeb of Science
  20. 20.↵
    Fry A, Littlejohns TJ, Sudlow C, et al. Comparison of Sociodemographic and Health-Related Characteristics of UK Biobank Participants With Those of the General Population. Am J Epidemiol 2017;186(9):1026–34. doi: 10.1093/aje/kwx246
    OpenUrlCrossRefPubMed
Back to top
PreviousNext
Posted July 11, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank
Xikang Fan, Cheng Yin, Jiayu Wang, Mingjia Yang, Hongxia Ma, Guangfu Jin, Mingyang Song, Zhibin Hu, Hongbing Shen, Dong Hang
medRxiv 2020.07.09.20149369; doi: https://doi.org/10.1101/2020.07.09.20149369
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank
Xikang Fan, Cheng Yin, Jiayu Wang, Mingjia Yang, Hongxia Ma, Guangfu Jin, Mingyang Song, Zhibin Hu, Hongbing Shen, Dong Hang
medRxiv 2020.07.09.20149369; doi: https://doi.org/10.1101/2020.07.09.20149369

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (430)
  • Allergy and Immunology (755)
  • Anesthesia (221)
  • Cardiovascular Medicine (3288)
  • Dentistry and Oral Medicine (364)
  • Dermatology (277)
  • Emergency Medicine (479)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1169)
  • Epidemiology (13359)
  • Forensic Medicine (19)
  • Gastroenterology (898)
  • Genetic and Genomic Medicine (5147)
  • Geriatric Medicine (481)
  • Health Economics (782)
  • Health Informatics (3264)
  • Health Policy (1140)
  • Health Systems and Quality Improvement (1190)
  • Hematology (429)
  • HIV/AIDS (1017)
  • Infectious Diseases (except HIV/AIDS) (14622)
  • Intensive Care and Critical Care Medicine (912)
  • Medical Education (476)
  • Medical Ethics (127)
  • Nephrology (522)
  • Neurology (4919)
  • Nursing (262)
  • Nutrition (727)
  • Obstetrics and Gynecology (882)
  • Occupational and Environmental Health (795)
  • Oncology (2519)
  • Ophthalmology (723)
  • Orthopedics (280)
  • Otolaryngology (347)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (543)
  • Pediatrics (1299)
  • Pharmacology and Therapeutics (550)
  • Primary Care Research (556)
  • Psychiatry and Clinical Psychology (4205)
  • Public and Global Health (7499)
  • Radiology and Imaging (1704)
  • Rehabilitation Medicine and Physical Therapy (1011)
  • Respiratory Medicine (980)
  • Rheumatology (479)
  • Sexual and Reproductive Health (497)
  • Sports Medicine (424)
  • Surgery (547)
  • Toxicology (72)
  • Transplantation (235)
  • Urology (205)